|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FBXO5 |
Gene summary for FBXO5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FBXO5 | Gene ID | 26271 |
| Gene name | F-box protein 5 | |
| Gene Alias | EMI1 | |
| Cytomap | 6q25.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9UKT4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26271 | FBXO5 | PTC07 | Human | Thyroid | PTC | 4.82e-02 | 5.30e-02 | 0.2044 |
| 26271 | FBXO5 | ATC13 | Human | Thyroid | ATC | 5.45e-11 | 1.91e-01 | 0.34 |
| 26271 | FBXO5 | ATC2 | Human | Thyroid | ATC | 5.78e-04 | 8.24e-01 | 0.34 |
| 26271 | FBXO5 | ATC4 | Human | Thyroid | ATC | 1.86e-03 | 2.43e-01 | 0.34 |
| 26271 | FBXO5 | ATC5 | Human | Thyroid | ATC | 2.04e-12 | 3.20e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1903320113 | Thyroid | PTC | regulation of protein modification by small protein conjugation or removal | 148/5968 | 242/18723 | 4.49e-21 | 8.10e-19 | 148 |
| GO:0031396113 | Thyroid | PTC | regulation of protein ubiquitination | 128/5968 | 210/18723 | 3.06e-18 | 3.27e-16 | 128 |
| GO:001605017 | Thyroid | PTC | vesicle organization | 163/5968 | 300/18723 | 4.74e-16 | 3.69e-14 | 163 |
| GO:0051258113 | Thyroid | PTC | protein polymerization | 154/5968 | 297/18723 | 5.35e-13 | 2.66e-11 | 154 |
| GO:0051348113 | Thyroid | PTC | negative regulation of transferase activity | 137/5968 | 268/18723 | 3.78e-11 | 1.36e-09 | 137 |
| GO:000734619 | Thyroid | PTC | regulation of mitotic cell cycle | 212/5968 | 457/18723 | 4.03e-11 | 1.44e-09 | 212 |
| GO:003304419 | Thyroid | PTC | regulation of chromosome organization | 102/5968 | 187/18723 | 1.04e-10 | 3.58e-09 | 102 |
| GO:0031397113 | Thyroid | PTC | negative regulation of protein ubiquitination | 55/5968 | 83/18723 | 1.26e-10 | 4.28e-09 | 55 |
| GO:004477218 | Thyroid | PTC | mitotic cell cycle phase transition | 196/5968 | 424/18723 | 3.17e-10 | 1.02e-08 | 196 |
| GO:2001020112 | Thyroid | PTC | regulation of response to DNA damage stimulus | 113/5968 | 219/18723 | 9.37e-10 | 2.77e-08 | 113 |
| GO:1903321113 | Thyroid | PTC | negative regulation of protein modification by small protein conjugation or removal | 59/5968 | 95/18723 | 1.26e-09 | 3.63e-08 | 59 |
| GO:0010639112 | Thyroid | PTC | negative regulation of organelle organization | 163/5968 | 348/18723 | 3.04e-09 | 8.39e-08 | 163 |
| GO:01400148 | Thyroid | PTC | mitotic nuclear division | 135/5968 | 287/18723 | 4.90e-08 | 1.04e-06 | 135 |
| GO:004578718 | Thyroid | PTC | positive regulation of cell cycle | 144/5968 | 313/18723 | 9.93e-08 | 1.99e-06 | 144 |
| GO:19019908 | Thyroid | PTC | regulation of mitotic cell cycle phase transition | 138/5968 | 299/18723 | 1.44e-07 | 2.78e-06 | 138 |
| GO:0007568111 | Thyroid | PTC | aging | 153/5968 | 339/18723 | 1.80e-07 | 3.34e-06 | 153 |
| GO:000705116 | Thyroid | PTC | spindle organization | 92/5968 | 184/18723 | 2.21e-07 | 3.92e-06 | 92 |
| GO:0051444113 | Thyroid | PTC | negative regulation of ubiquitin-protein transferase activity | 17/5968 | 19/18723 | 2.98e-07 | 5.09e-06 | 17 |
| GO:004593119 | Thyroid | PTC | positive regulation of mitotic cell cycle | 65/5968 | 121/18723 | 5.08e-07 | 8.26e-06 | 65 |
| GO:0001503110 | Thyroid | PTC | ossification | 176/5968 | 408/18723 | 9.26e-07 | 1.40e-05 | 176 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FBXO5 | SNV | Missense_Mutation | c.1063A>C | p.Thr355Pro | p.T355P | Q9UKT4 | protein_coding | tolerated(0.14) | benign(0.003) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| FBXO5 | deletion | In_Frame_Del | c.1204_1218delGGATTTGATTATTGT | p.Gly402_Cys406del | p.G402_C406del | Q9UKT4 | protein_coding | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| FBXO5 | SNV | Missense_Mutation | novel | c.1220C>T | p.Thr407Met | p.T407M | Q9UKT4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FBXO5 | SNV | Missense_Mutation | c.1086N>A | p.Phe362Leu | p.F362L | Q9UKT4 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FBXO5 | SNV | Missense_Mutation | c.668N>G | p.Ile223Ser | p.I223S | Q9UKT4 | protein_coding | deleterious(0.01) | benign(0.039) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FBXO5 | SNV | Missense_Mutation | rs199732439 | c.649N>T | p.Arg217Trp | p.R217W | Q9UKT4 | protein_coding | tolerated(0.17) | benign(0) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| FBXO5 | SNV | Missense_Mutation | rs766507735 | c.659N>G | p.Leu220Arg | p.L220R | Q9UKT4 | protein_coding | deleterious(0) | possibly_damaging(0.853) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FBXO5 | SNV | Missense_Mutation | c.927T>G | p.Phe309Leu | p.F309L | Q9UKT4 | protein_coding | tolerated(0.43) | benign(0) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FBXO5 | SNV | Missense_Mutation | c.329C>G | p.Thr110Ser | p.T110S | Q9UKT4 | protein_coding | tolerated(0.54) | benign(0.007) | TCGA-AY-A71X-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FBXO5 | SNV | Missense_Mutation | c.1073G>A | p.Arg358Gln | p.R358Q | Q9UKT4 | protein_coding | deleterious(0) | possibly_damaging(0.895) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |